Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2002 Feb 19;99(4):1749-51.
doi: 10.1073/pnas.042708299.

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

Joshua M Farber  1 , Edward A Berger
Affiliations
Comment

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

Joshua M Farber et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sequential receptor interactions involved in HIV-1 entry into T cells. In the report by Trkola et al. (3), the initial virus population used CCR5 but not CXCR4.
Figure 2
Figure 2
Potential viral escape mechanisms from CCR5-targeted inhibitor AD101. The normal gp120/CCR5 interaction (A) is blocked when AD101 (*) binds specifically to CCR5, thereby preventing membrane fusion and virus entry (B). Several mutational variations in gp120 can be envisioned that would lead to viral escape from AD101, including: change (or expansion) of coreceptor usage to enable CXCR4 usage (C); increased affinity of gp120 for CCR5, thereby enabling more efficient competition with AD101 for binding to CCR5 (D); acquisition of the ability of gp120 to function with CCR5 bound to AD101. In the study by Trkola et al., no evidence for escape mechanism C was detected. The authors propose a sequential resistance pathway, involving first adaption to more efficient use of CCR5 (D) followed by selection for variants that can use the drug-bound form of CCR5 (E).
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Richman D D. Nature (London) 2001;410:995–1001. - PubMed
    1. Eckert D M, Kim P S. Annu Rev Biochem. 2001;70:777–810. - PubMed
    1. Trkola A, Kuhmann S E, Strizki J M, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, et al. Proc Natl Acad Sci USA. 2002;99:395–400. - PMC - PubMed
    1. Berger E A, Murphy P M, Farber J M. Annu Rev Immunol. 1999;17:657–700. - PubMed
    1. Fauci A S. Nature (London) 1996;384:529–534. - PubMed

LinkOut - more resources